Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 1;90(1):97-105.
doi: 10.1097/QAI.0000000000002922.

Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV

Affiliations

Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV

Caitlin Wei-Ming Watson et al. J Acquir Immune Defic Syndr. .

Abstract

Background: To examine longitudinal neurocognitive decline among Latino, non-Latino Black, and non-Latino White people with HIV (PWH) and factors that may explain ethnic/racial disparities in neurocognitive decline.

Methods: Four hundred ninety nine PWH (13.8% Latino, 42.7% Black, 43.5% White; baseline age: M = 43.5) from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study completed neurocognitive, neuromedical, and laboratory assessments every 6-12 months with up to 5 years of follow-up. Longitudinal neurocognitive change was determined via published regression-based norms. Survival analyses investigated the relationship between ethnicity/race and neurocognitive change, and baseline and time-dependent variables that may explain ethnic/racial disparities in neurocognitive decline, including socio-demographic, HIV-disease, medical, psychiatric, and substance use characteristics.

Results: In Cox proportional hazard models, hazard ratios for neurocognitive decline were increased for Latino compared with White PWH (HR = 2.25, 95% CI = 1.35 to 3.73, P = 0.002), and Latino compared with Black PWH (HR = 1.86, 95% CI = 1.14 to 3.04, P = 0.013), with no significant differences between Black and White PWH (P = 0.40). Comorbidities, including cardiometabolic factors and more severe neurocognitive comorbidity classification, accounted for 33.6% of the excess hazard for Latino compared with White PWH, decreasing the hazard ratio associated with Latino ethnicity (HR = 1.83, 95% CI = 1.06 to 3.16, P = 0.03), but did not fully account for elevated risk of decline.

Conclusions: Latino PWH may be at higher risk of early neurocognitive decline compared with Black and White PWH. Comorbidities accounted for some, but not all, of this increased risk among Latino PWH. Future research examining institutional, sociocultural, and biomedical factors, including structural discrimination and age-related biomarkers, may further explain the observed disparities.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Neurocognitive change (decline, stable, improve) by ethnicity/race. The overall model showed significant ethnic/racial differences in the proportion of participants who declined, remained stable, or improved neurocognitively 2 = 11.84, df = 4, p = 0.019). Latino PWH were at higher risk of neurocognitive decline compared to White 2 = 10.24, df = 1, p = 0.001) and Black 2 = 5.59, df = 1, p = 0.018) PWH, while Black and White PWH did not differ 2 = 0.91, df = 1, p = 0.34).
Figure 2.
Figure 2.
Neurocognitive decline over study follow-up by ethnicity/race. In a Kaplan-Meier survival analysis, the pattern of decline over years of follow-up differed significantly by ethnicity/race (p = 0.005). In pairwise log-rank tests, Latino PWH declined faster and had a higher proportion of neurocognitive decliners compared to White (HR = 2.24, 95% CI 1.24–4.05, p = 0.001) and Black (HR = 1.86, 95% CI 1.07–3.25, p = 0.01) PWH. Black and White PWH showed similar trajectories of neurocognitive decline over study follow-up (HR = 1.21, 95% CI 0.78–1.87, p = 0.40).

References

    1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. - PMC - PubMed
    1. CDC. HIV Surveillance Report, 2018 (Updated). 2020.
    1. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clinical infectious diseases. 2013;57(8):1164–1171. - PubMed
    1. Buchacz K, Baker R, Palella F, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antiviral Therapy. 2013;18(1):65–75. - PubMed
    1. Rawlings MK, Masters HL. Comorbidities and challenges affecting African Americans with HIV infection. Journal of the National Medical Association. 2008;100(12):1477–1481. - PubMed

Publication types